Financial Performance - As of September 30, 2024, cash, cash equivalents, and marketable securities totaled $75.3 million, down from $108.3 million at the end of 2023, reflecting a decrease of $33.0 million[7] - Research and development expenses for Q3 2024 were $8.8 million, a decrease from $11.0 million in Q3 2023, primarily due to lower costs on other programs[7] - General and administrative expenses decreased to $3.7 million in Q3 2024 from $4.6 million in Q3 2023, attributed to lower payroll and stock compensation expenses[7] - The net loss for Q3 2024 was $11.5 million, compared to a net loss of $14.3 million in Q3 2023, indicating an improvement in financial performance[7] - NextCure expects to fund operations into the second half of 2026 with current cash reserves[1] Clinical Development - NextCure plans to prioritize resources on LNCB74 (B7-H4 ADC) with an IND submission expected by year-end 2024[1] - The response rate for ICI naïve ovarian cancer patients in the NC410 study was 25%, with 5 out of 20 patients showing partial responses[5] - The disease control rate (DCR) for the 100 mg CRC cohort was 47% based on 36 patients, with a median disease control duration of 8.5 months[5] - NextCure is seeking a partner to advance the NC410 program following the conclusion of the current trial[2] - Preclinical data for LNCB74 will be presented at the SITC annual meeting in November 2024[3]
NextCure(NXTC) - 2024 Q3 - Quarterly Results